Sumitomo Mitsui DS Asset Management Company Ltd Has $3.48 Million Position in Humana Inc. (NYSE:HUM)

Sumitomo Mitsui DS Asset Management Company Ltd reduced its stake in Humana Inc. (NYSE:HUM) by 1.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 13,699 shares of the insurance provider’s stock after selling 264 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Humana were worth $3,476,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Creative Financial Designs Inc. ADV raised its stake in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 61 shares during the period. Ashton Thomas Securities LLC purchased a new stake in shares of Humana during the 3rd quarter valued at approximately $31,000. Your Advocates Ltd. LLP grew its stake in Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares in the last quarter. Atwood & Palmer Inc. raised its holdings in Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 60 shares during the period. Finally, LRI Investments LLC lifted its position in shares of Humana by 1,021.4% during the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after acquiring an additional 143 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM stock opened at $274.06 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a market capitalization of $33.00 billion, a P/E ratio of 24.27, a PEG ratio of 2.11 and a beta of 0.56. The stock has a 50 day moving average price of $274.21 and a two-hundred day moving average price of $298.14.

Analysts Set New Price Targets

A number of analysts recently issued reports on HUM shares. Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Truist Financial increased their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. TD Cowen increased their target price on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Wells Fargo & Company decreased their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, Bank of America raised Humana from an “underperform” rating to a “neutral” rating and lifted their price objective for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Humana currently has an average rating of “Hold” and an average target price of $297.68.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.